Retatrutide (10mg)

Retatrutide is a GGG tri-agonist peptide built to activate the GLP-1, GIP, and glucagon receptors at the same time. For laboratories evaluating it, that three-receptor design gives a signaling profile single-agonist and dual-agonist peptides cannot reproduce. Modern Bio supplies retatrutide as a research-use-only material, synthesized for in-vitro and animal-model work and backed by third-party verified purity, so the data you gather rests on consistent, documented quality.

Product specifications

Retatrutide ships as a lyophilized powder sealed in a glass vial. The core identifiers and handling data are listed below.

Property	Detail
Application	Triple-agonist metabolic pathway research
Appearance	Solid, white powder in a 3 mL glass vial
Chemical formula	C223H343F3N46O70
PubChem SID	474492235
CAS number	2381089-83-2
Molecular weight	~4,845.44 g/mol
Synonyms	Retatrutide, GLP3, GGG Peptide, Triple G Peptide, LY3437943, GGG tri-agonist, "Reta", GLP-3R
Storage	Sealed at −20°C, away from heat, light, and moisture

What is retatrutide?

Retatrutide (LY3437943) is a synthetic peptide engineered to interact with three receptor systems: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). Because it is designed to engage all three at once, the scientific literature classifies it as a tri-receptor agonist. ^[1]

In the lab, retatrutide gives researchers a way to study coordinated incretin and glucagon receptor signaling, receptor pharmacology, and the downstream intracellular pathways that follow receptor engagement. Its multi-receptor design sets it apart from single- and dual-receptor peptide analogs and lets investigators examine how those pathways interact inside controlled experimental models.

Current understanding of retatrutide comes from in-vitro studies, animal models, and ongoing clinical research. Findings should be read within their own experimental settings and not treated as established clinical outcomes.

Modern Bio supplies retatrutide as a high-purity, lyophilized research compound in a single 10 mg vial. The material is intended strictly for laboratory research and is not approved for human or veterinary use.

Retatrutide mechanism of action (research only)

Retatrutide is studied for its ability to engage three receptor systems central to incretin and glucagon signaling: GLP-1R, GIPR, and GCGR. Where single- and dual-receptor analogs address one or two of those pathways, retatrutide gives researchers a model for probing coordinated signaling across all three at once.

The mechanistic picture here is drawn from biochemical assays, cell-culture work, animal models, and ongoing clinical research. Everything below reflects observations from experimental systems and belongs strictly in a research context.

Structural and chemical basis

Retatrutide is a synthetic peptide of 39 amino acids carrying a lipid modification that promotes reversible albumin binding. In experimental systems, that structural feature tracks with prolonged molecular stability and sustained receptor engagement, which makes the compound useful for studies of time-dependent receptor signaling and pharmacological behavior.

GLP-1 receptor signaling

A large share of retatrutide research centers on GLP-1 receptor signaling. Experimental models use this pathway to trace the intracellular events that follow receptor engagement, including second-messenger systems and receptor-mediated cellular communication. ^[2] Inside the tri-receptor framework, GLP-1R activity is examined alongside GIPR and GCGR so that investigators can characterize coordinated pharmacology rather than one pathway in isolation.

GIP receptor signaling

Retatrutide is also studied for its interaction with the glucose-dependent insulinotropic polypeptide receptor. Researchers use experimental models to look at how GIPR activation feeds receptor cross-talk, shapes intracellular signaling dynamics, and contributes to the combined response when several receptor systems fire together. ^[3] The focus in this work is receptor biology and signaling mechanism, not physiological outcome.

Glucagon receptor signaling

The glucagon receptor component is what most clearly separates retatrutide from GLP-1 and GLP-1/GIP peptides. Experimental studies examine how GCGR engagement shapes receptor pharmacology and intracellular signaling inside multi-receptor models, opening up signaling relationships that single-receptor compounds simply cannot expose. ^[4]

Integrated tri-receptor signaling

Because retatrutide engages three receptor systems within one experimental model, it is often used to study receptor coordination, pathway interaction, and signal integration across incretin and glucagon networks. Researchers lean on these systems to characterize receptor cross-talk, downstream signaling behavior, and the timing of multi-receptor activation under controlled conditions. ^[5] Rather than standing for one mechanism, retatrutide works as a research tool for asking how several receptor-mediated pathways interact inside a complex biological system.

Modern Bio supplies retatrutide strictly for laboratory research. The material is meant only for investigating GLP-1, GIP, and glucagon receptor biology and is not approved for clinical, diagnostic, therapeutic, human, or veterinary use.

Retatrutide research applications (observations from studies)

Retatrutide turns up across preclinical research, translational studies, and ongoing clinical investigation as a multi-receptor peptide for exploring incretin and glucagon receptor biology. Its simultaneous engagement of GLP-1R, GIPR, and GCGR gives researchers a model for coordinated receptor signaling that no single-receptor analog can supply.

The observations below come from biochemical studies, cell-based assays, animal models, and ongoing clinical work. Read them within their own research settings; none of them stand in for established clinical outcomes.

Multi-receptor signaling research

The headline use for retatrutide is investigating coordinated signaling across the GLP-1, GIP, and glucagon receptor systems. Experimental models let researchers examine receptor cross-talk, signal integration, and the downstream intracellular response when several peptide receptors are engaged at once, which in turn sharpens the picture of how interconnected pathways behave in a controlled setting.

Receptor pharmacology and comparative studies

Retatrutide frequently anchors comparative research across single-, dual-, and tri-receptor peptide designs. These studies weigh differences in binding characteristics, signaling duration, pathway interaction, and pharmacological behavior between the classes, supporting mechanistic work on receptor selectivity without asserting superiority or clinical performance. ^[5]

Endocrine and metabolic signaling models

Researchers also use retatrutide to probe endocrine networks that run through incretin and glucagon receptor pathways. Experimental systems look at how coordinated receptor activation moves through intracellular cascades and the wider regulatory networks tied to peptide-hormone biology, with the aim of better understanding receptor-mediated communication rather than establishing physiological effect.

Translational research applications

Because retatrutide folds three receptor activities into one peptide, it serves translational research that connects mechanistic bench findings to broader questions in peptide pharmacology and receptor biology. Ongoing clinical research continues to characterize its pharmacological properties and to inform the next round of multi-receptor peptide design.

Modern Bio supplies retatrutide strictly for laboratory research. The material is meant only for investigating peptide receptor biology and multi-receptor signaling and is not approved for clinical, therapeutic, diagnostic, human, or veterinary use.

Retatrutide vs. semaglutide vs. tirzepatide

Researchers often line retatrutide up against semaglutide and tirzepatide because all three are peptide analogs that engage incretin-related receptor systems. What separates them is how many receptor pathways each one is built to study, which is what makes each useful for a different corner of receptor pharmacology and signaling research.

Parameter	Retatrutide	Semaglutide	Tirzepatide
Molecular classification	Synthetic tri-receptor peptide	Synthetic GLP-1 receptor agonist	Synthetic dual GIP/GLP-1 receptor agonist
Primary receptor targets	GLP-1R, GIPR, and GCGR	GLP-1R	GLP-1R and GIPR
Primary research focus	Multi-receptor signaling, receptor cross-talk, and pathway-interaction studies	GLP-1 receptor pharmacology and signaling	Dual incretin receptor signaling and pathway-interaction studies
Mechanistic complexity	Tri-receptor signaling model	Single-receptor signaling model	Dual-receptor signaling model
Typical research models	Cell culture, biochemical assays, animal models, ongoing clinical research	Cell culture, biochemical assays, animal models, clinical research	Cell culture, biochemical assays, animal models, clinical research
Intended research role	Coordinated multi-receptor signaling	GLP-1 receptor biology	Dual incretin receptor biology
Regulatory status	Research compound under clinical investigation	Approved medicine in multiple jurisdictions	Approved medicine in multiple jurisdictions

Retatrutide laboratory safety & handling (research use only)

Retatrutide arrives as a synthetic, lyophilized research peptide meant only for laboratory investigation. It should be handled by qualified personnel in controlled research settings, in line with institutional policy, laboratory safety procedure, and applicable regulation.

Because it is an investigational research material, laboratories should adopt handling practices that protect material integrity, traceability, and reproducibility. The exact procedures will vary with study design, analytical method, and institutional risk assessment.

Laboratory handling guidelines

Best-practice guidance covers:

• Follow institutional standard operating procedures, chemical hygiene plans, and approved research protocols.
• Wear appropriate personal protective equipment, including a lab coat, gloves, and eye protection.
• Handle the material using procedures suited to research-grade peptide compounds in controlled laboratory environments.
• Use engineering controls where institutional safety policy or a risk assessment calls for them.
• Keep clean working conditions to limit contamination risk and support experimental consistency.
• Record lot numbers, storage conditions, and handling activity as part of routine quality control.
• Retain Certificates of Analysis, batch documentation, and quality records to support traceability, audit readiness, and reproducibility.
• Follow institutional procedures for spill response, waste management, and incident reporting.

Storage and stability considerations

Sound storage practice preserves product quality and reduces experimental variability.

• Store the material under the conditions given in the product documentation.
• Protect it from excess heat, moisture, and direct light.
• Keep storage conditions consistent for the length of the study.
• Track inventory and storage records as part of laboratory quality assurance.

Consistent handling, documentation, and storage all help produce reliable results and hold reproducibility steady across research programs.

Modern Bio supplies retatrutide strictly for laboratory research. The material is not approved for clinical, therapeutic, diagnostic, human, or veterinary use and should be handled only in qualified laboratory settings.

Certificate of analysis (COA) & quality assurance

Every retatrutide batch ships with a third-party verified Certificate of Analysis, so quality control stays transparent and research-grade. The COA reports:

• Purity assessment (HPLC or reverse-phase chromatography)
• Mass-spectrometry identity confirmation
• Lot number, testing date, and method documentation

Researchers can request a sample COA (PDF) before purchase to confirm testing parameters, analytical methods, and batch consistency, and we encourage independent testing and verification of every lot.

Frequently asked questions

Where can I buy retatrutide online?

Researchers can order retatrutide directly from Modern Bio, a US supplier of high-purity research compounds produced under strict manufacturing standards and independently verified to support reliable, reproducible research.

What is retatrutide used for in laboratory research?

Retatrutide is studied as a synthetic tri-receptor peptide for investigating GLP-1, GIP, and glucagon receptor signaling in controlled laboratory models. Researchers use it to examine receptor pharmacology, pathway interaction, and multi-receptor signaling. Modern Bio supplies it exclusively for research use.

How is retatrutide different from semaglutide and tirzepatide?

The main difference is receptor scope. Semaglutide engages the GLP-1 receptor, tirzepatide targets both GLP-1 and GIP receptors, and retatrutide is engineered to interact with GLP-1, GIP, and glucagon receptor pathways. Those differences suit each compound to a different area of receptor signaling and pharmacology research.

Is retatrutide approved for human use?

No. Retatrutide remains under clinical investigation and is not approved for general therapeutic use. Modern Bio supplies it in lyophilized peptide form strictly as a laboratory research compound, not for human or veterinary use.

Does Modern Bio supply high-purity retatrutide?

Yes. Modern Bio supplies high-purity, research-grade retatrutide made for laboratory research. Every batch undergoes independent third-party testing, and Certificates of Analysis are available to support quality assurance and reproducible research.

Does Modern Bio provide Certificates of Analysis for retatrutide?

Yes. A Certificate of Analysis is available for every batch so researchers can verify identity, purity, and batch consistency before use. COAs are produced after analytical testing by independent third-party laboratories, and you can usually trace each certificate back to the testing facility.

Why do researchers study tri-receptor peptides like retatrutide?

Tri-receptor peptides let researchers investigate coordinated signaling across several receptor systems within one experimental model. That supports comparative study of receptor interaction, signaling dynamics, and multi-receptor pharmacology under controlled laboratory conditions.

References

1. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther. 2024;9:234.
2. Meloni AR, DeYoung MB, Lowe C, Parkes DG. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence. Diabetes Obes Metab. 2013;15(1):15-27.
3. James-Okoro P-P, Lewis JE, Gribble FM, Reimann F. The role of GIPR in food intake control. Front Endocrinol. 2025;16:1532076.
4. Villarroya F, Peyrou M, Giralt M. Adipose tissue, at the core of the action of incretin and glucagon-based drugs. Curr Obes Rep. 2025;14(1):67.
5. Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D. Triple agonism based therapies. Curr Cardiovasc Risk Rep. 2025;19(1):18.

For research use only. Not for human or veterinary use, diagnosis, or treatment. Not a drug, food, or cosmetic. Sold only to qualified research professionals aged 21 or older.